Bayesian Capital Management, LP Allakos Inc. Transaction History

Bayesian Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $12,960 - $18,900	-3,600 Reduced 18.22%	16,163 $70,000
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $84,980 - $163,440	19,763 New	19,763 $87,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $47,894 - $97,057	15,859 New	15,859 $97,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $281,532 - $590,971	-6,328 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $8,510 - $17,629	128 Added 2.06%	6,328 $603,000
Q3 2019 Nov 13, 2019	BUY	$31.0 - $89.73 $192,200 - $556,326	6,200 New	6,200 $488,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.